<DOC>
	<DOC>NCT00201864</DOC>
	<brief_summary>The purpose of this trial is to evaluate time to progression in women with hormone responsive advanced breast cancer treated with a combination of exemestane and fulvestrant.</brief_summary>
	<brief_title>Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>Proven breast cancer Metastatic or locally advanced breast cancer Hormonally responsive disease defined as estrogen (ER) and/ or progesterone receptor (PR) positive (&gt;10% staining by immunohistochemistry) Postmenopausal status No more than 1 prior chemotherapy for stage IV metastatic breast cancer allowed ECOG (Eastern Cooperative Oncology Group) performance status 02 Adequate organ function No prior Exemestane or Fulvestrant Uncontrolled intercurrent illness including but not limited to: ongoing or active infection symptomatic congestive heart failure unstable angina pectoris cardiac arrhythmia myocardial infarction within the last 3 months psychiatric illness/social situations that would limit compliance with study Lymphangitic pulmonary disease; carcinomatous meningitis, bone marrow only metastases; and a rising tumor marker without any other site of metastatic disease. Presence of bleeding diathesis or coagulopathy, patients requiring coumadin</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Postmenopausal</keyword>
	<keyword>Women</keyword>
</DOC>